rabeprazole has been researched along with Gastric Ulcer in 57 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers." | 9.30 | Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. ( Baik, GH; Bang, CS; Choi, MH; Jang, HJ; Kae, SH; Kim, HY; Park, SW; Seo, SI; Shin, SP; Shin, WG; Yang, YJ, 2019) |
| "Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection." | 9.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "To evaluate the effect of a single dose of rebeprazole (RAB) versus omeprazole (OME) on acid suppression and symptom relief in patients with gastric ulcer." | 9.11 | [The effect of rabeprazole on gastric pH in patients with gastric ulcer]. ( Ke, MY, 2004) |
| "In this randomized, double-blind, multicentre study, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers." | 9.08 | Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1998) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "We compared the PGE(2) and LTB(4) levels and the expression levels of cyclooxygenase (COX)-1 and COX-2 mRNA in the gastric mucosa in gastric ulcer patients between the group treated for 8 weeks with a PPI, rabeprazole (PPI group; n=5), and the group treated for 8 weeks with an H(2) blocker, ranitidine (H(2) blocker group; n=6), as well as in nonulcer subjects (control group; n=5)." | 7.74 | Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. ( Fujiwara, S; Horie, T; Ishikawa, M; Ito, S; Iuchi, A; Okazaki, M; Shimizu, I; Shiraishi, T; Yamamoto, H, 2007) |
| "According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers." | 5.30 | Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. ( Baik, GH; Bang, CS; Choi, MH; Jang, HJ; Kae, SH; Kim, HY; Park, SW; Seo, SI; Shin, SP; Shin, WG; Yang, YJ, 2019) |
| "In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66)." | 5.22 | Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy. ( Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R, 2016) |
| "Patients in the vonoprazan group (n = 75) were prospectively enrolled, whereas patients in the PPI group (n = 150) were selected for a 2:1 matched historical control cohort according to baseline characteristics including gastric ulcer size immediately following ESD, age, sex and status of Helicobacter pylori infection." | 5.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "To evaluate the effect of a single dose of rebeprazole (RAB) versus omeprazole (OME) on acid suppression and symptom relief in patients with gastric ulcer." | 5.11 | [The effect of rabeprazole on gastric pH in patients with gastric ulcer]. ( Ke, MY, 2004) |
| "A total of 102 Helicobacter pylori-positive patients with gastric ulcer were randomly allocated to three groups: rabeprazole 10 mg (RAC10), rabeprazole 20 mg (RAC20) or rabeprazole 40 mg (RAC40) plus amoxicillin 750 mg and clarithromycin 200 mg twice daily for 7 days." | 5.09 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. ( Asaka, M; Hige, S; Hokari, K; Ishizuka, J; Kagaya, H; Kato, M; Komatsu, Y; Kudo, M; Miyagishima, T; Mizushima, T; Nishikawa, K; Saito, M; Sugiyama, T; Takeda, H, 2001) |
| "In this randomized, double-blind, multicentre study, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers." | 5.08 | Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1998) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| " To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide-three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing)." | 4.81 | Efficacy of rabeprazole once daily for acid-related disorders. ( Bardhan, KD; Barth, J; Lanza, F; Niecestro, R; Perdomo, C, 2001) |
| " Healing rates for rabeprazole were equivalent to omeprazole in all indications, and superior (GORD healing and duodenal ulcer healing) or equivalent (gastric ulcer healing) to the histamine 2-receptor antagonist ranitidine." | 4.80 | The benefit/risk profile of rabeprazole, a new proton-pump inhibitor. ( Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C, 2000) |
| "A retrospective study was conducted among 64 patients with gastric ulcers of spleen deficiency and dampness heat admitted to our hospital from September 2019 to May 2020, and they were divided at a ratio of 1 : 1 into an observation group (rabeprazole sodium enteric-coated capsules plus Erzhu Yiren Decoction) and a control group (rabeprazole sodium enteric-coated capsules) based on different treatment methods." | 4.12 | A Retrospective Trial Exploring Erzhu Yiren Decoction in Gastric Ulcer with Spleen Deficiency and Dampness-Heat. ( Shan, Z; Zhang, T, 2022) |
| "We compared the PGE(2) and LTB(4) levels and the expression levels of cyclooxygenase (COX)-1 and COX-2 mRNA in the gastric mucosa in gastric ulcer patients between the group treated for 8 weeks with a PPI, rabeprazole (PPI group; n=5), and the group treated for 8 weeks with an H(2) blocker, ranitidine (H(2) blocker group; n=6), as well as in nonulcer subjects (control group; n=5)." | 3.74 | Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. ( Fujiwara, S; Horie, T; Ishikawa, M; Ito, S; Iuchi, A; Okazaki, M; Shimizu, I; Shiraishi, T; Yamamoto, H, 2007) |
| "Patients with gastric ulcers were allocated to an untreated control group, consisting of patients with active ulcers (GA), healing ulcers (GH), and ulcer scars (GS) or a PPI group (P; given rabeprazole at 20 mg/day), or an H2-blocker group (H; given nizatidine at 800 mg/day)." | 3.73 | Effects of antisecretory agents on angiogenesis during healing of gastric ulcers. ( Akimoto, M; Hashimoto, H; Maeda, A; Shigemoto, M; Yamashita, K, 2005) |
| " We examined the roles of TNF-alpha and dynamics of chemokine expression in gastric ulceration including ulcer recurrence and indomethacin-induced injury." | 3.72 | Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha. ( Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Shiba, M; Tominaga, K; Watanabe, T, 2004) |
| " pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b." | 3.72 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. ( Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK, 2003) |
| " The aim of the present study was to investigate the pathogenesis of these gastric ulcers and to examine the effects of two antiulcer drugs; a proton pump inhibitor (2{[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methyl-sulfinyl}-1H -benzimidazole sodium salt, rabeprazole) and a mucosal protective drug (geranylgeranylacetone, GGA), on the gastric ulcers." | 3.70 | Bile reflux due to disturbed gastric movement is a cause of spontaneous gastric ulcer in W/Wv mice. ( Azuma, T; Dojyo, M; Ito, S; Ito, Y; Kato, T; Kohli, Y; Kuriyama, M; Miyaji, H; Suto, H; Yamazaki, Y, 1999) |
| "This study was designed to clarify effects of proton pump inhibitors, E-3810(2-([4-(3-methoxypropoxy)-3methylpyridine-2-yl]methyl- sulfinyl)-1H-benzimidazol sodium salt) and omeprazole (CAS 73590-58-6), on water immersion stress-induced gastric ulcers in relation to mucosal prostaglandins (PGs) and leukotrienes (LTs)." | 3.68 | Effects of two benzimidazoles as proton pump inhibitors on water immersion stress-induced gastric ulcers in rats. ( Goto, H; Hoshino, H; Kuroiwa, M; Nakazawa, S; Ohara, A; Ozawa, T; Sugiyama, S; Tsukamoto, Y, 1991) |
| "Rabeprazole prevents the recurrence of peptic ulcers with no evidence of a major dose-response effect in subjects on low-dose aspirin therapy." | 2.79 | Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. ( Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014) |
| "Although endoscopic submucosal dissection (ESD)-induced ulcers heal faster and recur less often than non-iatrogenic gastric ulcers, the optimal dosage and duration of proton pump inhibitor treatment for ESD-induced ulcers remain unclear." | 2.78 | Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer. ( Hong, JH; Jo, KW; Kim, BR; Kim, HS; Kim, JW; Park, HJ; Park, SY, 2013) |
| "pantoprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| "Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD." | 2.69 | Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. ( Beker, JA; Bjaaland, T; Dekkers, C; Finnegan, V; Humphries, TJ; Thjodleifsson, B, 2000) |
| "Twenty-four healthy male volunteers were studied on the 7th day of morning dosing with either placebo or rabeprazole 10, 20 or 40 mg in a crossover fashion." | 2.69 | A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. ( Blanshard, C; Millson, C; Pounder, RE; Sercombe, J; Williams, MP, 2000) |
| ") occurring after the start of rabeprazole treatment were handled as adverse events." | 1.35 | Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan. ( Mizokami, Y, 2009) |
| "Group 1 comprised 47 patients with GERD and group 2 49 patients with gastric and duodenal UD." | 1.35 | [Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer]. ( Andreev, NG; Beliantseva, EV; Golubev, NN; Maev, IV; Odintsova, AN; Samsonov, AA, 2009) |
| "Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs." | 1.35 | Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. ( Marelli, S; Pace, F; Pallotta, S, 2008) |
| "Pretreatment with indomethacin did not influence the cytoprotective effect of rabeprazole." | 1.31 | Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide. ( Arakawa, T; Fujiwara, Y; Higuchi, K; Tominaga, K; Watanabe, T, 2000) |
| "Rabeprazole has a favourable profile with rapid action and good safety." | 1.31 | [Pharma-clinics medication of the month. Rabeprazole (Pariet)]. ( Louis, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (12.28) | 18.2507 |
| 2000's | 34 (59.65) | 29.6817 |
| 2010's | 15 (26.32) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, T | 1 |
| Shan, Z | 1 |
| Yamasaki, A | 1 |
| Yoshio, T | 1 |
| Muramatsu, Y | 1 |
| Horiuchi, Y | 1 |
| Ishiyama, A | 1 |
| Hirasawa, T | 1 |
| Tsuchida, T | 1 |
| Sasaki, Y | 1 |
| Fujisaki, J | 1 |
| Bang, CS | 1 |
| Shin, WG | 1 |
| Seo, SI | 1 |
| Choi, MH | 1 |
| Jang, HJ | 1 |
| Park, SW | 1 |
| Kae, SH | 1 |
| Yang, YJ | 1 |
| Shin, SP | 1 |
| Baik, GH | 1 |
| Kim, HY | 1 |
| Iwakiri, R | 2 |
| Higuchi, K | 3 |
| Kato, M | 2 |
| Fujishiro, M | 2 |
| Kinoshita, Y | 1 |
| Watanabe, T | 3 |
| Takeuchi, T | 1 |
| Yamauchi, M | 1 |
| Sanomura, M | 1 |
| Nakagawa, H | 1 |
| Sugisaki, N | 1 |
| Okada, Y | 1 |
| Ogawa, H | 1 |
| Arakawa, T | 3 |
| Fujimoto, K | 2 |
| Howden, CW | 1 |
| Lee, HJ | 1 |
| Kim, JI | 2 |
| Lee, JS | 1 |
| Jun, EJ | 1 |
| Oh, JH | 1 |
| Cheung, DY | 2 |
| Chung, WC | 1 |
| Kim, BW | 1 |
| Kim, SS | 1 |
| Nakamura, K | 1 |
| Ihara, E | 1 |
| Akiho, H | 1 |
| Akahoshi, K | 1 |
| Harada, N | 1 |
| Ochiai, T | 1 |
| Nakamura, N | 1 |
| Ogino, H | 1 |
| Iwasa, T | 1 |
| Aso, A | 1 |
| Iboshi, Y | 1 |
| Takayanagi, R | 1 |
| Kagawa, T | 1 |
| Iwamuro, M | 1 |
| Ishikawa, S | 1 |
| Ishida, M | 1 |
| Kuraoka, S | 1 |
| Sasaki, K | 1 |
| Sakakihara, I | 1 |
| Izumikawa, K | 1 |
| Yamamoto, K | 1 |
| Takahashi, S | 1 |
| Tanaka, S | 1 |
| Matsuura, M | 1 |
| Hasui, T | 1 |
| Wato, M | 1 |
| Inaba, T | 1 |
| Pallotta, S | 1 |
| Pace, F | 1 |
| Marelli, S | 1 |
| Li, Y | 1 |
| Wang, XY | 1 |
| Shen, SR | 1 |
| Pellicano, R | 1 |
| Osipenko, MF | 1 |
| Konstantinov, VI | 1 |
| Moiseenko, EE | 1 |
| Bikbulatova, EA | 1 |
| Nishino, M | 1 |
| Sugimoto, M | 1 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Shirai, N | 1 |
| Ikuma, M | 1 |
| Tanaka, T | 1 |
| Sugimura, H | 1 |
| Hishida, A | 1 |
| Furuta, T | 1 |
| Tan, VP | 1 |
| Wong, BC | 2 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| U-Saif, R | 1 |
| Khan, BA | 1 |
| Yatoo, GN | 1 |
| Shah, AH | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Maev, IV | 1 |
| Samsonov, AA | 1 |
| Beliantseva, EV | 1 |
| Golubev, NN | 1 |
| Odintsova, AN | 1 |
| Andreev, NG | 1 |
| Mizokami, Y | 1 |
| Fujiwara, S | 2 |
| Morita, Y | 1 |
| Toyonaga, T | 1 |
| Kawakami, F | 1 |
| Itoh, T | 1 |
| Yoshida, M | 1 |
| Kutsumi, H | 1 |
| Azuma, T | 2 |
| Niimi, K | 1 |
| Goto, O | 1 |
| Kodashima, S | 1 |
| Minatsuki, C | 1 |
| Hirayama, I | 1 |
| Mochizuki, S | 1 |
| Ono, S | 1 |
| Yamamichi, N | 1 |
| Kakushima, N | 1 |
| Ichinose, M | 1 |
| Koike, K | 1 |
| Choi, HS | 1 |
| Chun, HJ | 1 |
| Park, SH | 2 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Kim, YS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Murata, T | 1 |
| Kawashima, M | 1 |
| Terayama, Y | 1 |
| Okamura, Y | 1 |
| Takeno, S | 1 |
| Takahashi, Y | 1 |
| Moroga, T | 1 |
| Yamashita, S | 1 |
| Kawahara, K | 1 |
| Park, HJ | 1 |
| Kim, HS | 1 |
| Kim, BR | 1 |
| Park, SY | 1 |
| Hong, JH | 1 |
| Jo, KW | 1 |
| Kim, JW | 1 |
| Vasil'ev, IuV | 1 |
| Kas'ianenko, VI | 1 |
| Minushkin, ON | 1 |
| Zverkov, IV | 1 |
| Aronova, OV | 1 |
| Shuleshova, AG | 1 |
| Murakami, K | 1 |
| Sato, R | 1 |
| Okimoto, T | 1 |
| Nasu, M | 1 |
| Fujioka, T | 1 |
| Kodama, M | 1 |
| Kagawa, J | 1 |
| Sato, S | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Sorba, G | 1 |
| Galli, U | 1 |
| Cena, C | 1 |
| Fruttero, R | 1 |
| Gasco, A | 1 |
| Morini, G | 1 |
| Adami, M | 1 |
| Coruzzi, G | 1 |
| Brenciaglia, MI | 1 |
| Dubini, F | 1 |
| Lee, SB | 1 |
| Park, SJ | 1 |
| Ryu, JK | 1 |
| Lee, JK | 1 |
| Kim, HJ | 1 |
| Bae, JS | 1 |
| Jung, HS | 1 |
| Park, SM | 1 |
| Hamaguchi, M | 1 |
| Shiba, M | 1 |
| Tominaga, K | 2 |
| Fujiwara, Y | 2 |
| Matsumoto, T | 1 |
| Kotaira, J | 1 |
| Ke, MY | 1 |
| Akimoto, M | 1 |
| Hashimoto, H | 1 |
| Shigemoto, M | 1 |
| Maeda, A | 1 |
| Yamashita, K | 1 |
| Ando, T | 2 |
| Kato, H | 1 |
| Sugimoto, N | 1 |
| Nagao, Y | 1 |
| Seto, N | 1 |
| Hongo, H | 1 |
| Kajikawa, H | 1 |
| Isozaki, Y | 1 |
| Shimozawa, M | 1 |
| Naito, Y | 2 |
| Yoshida, N | 2 |
| Ishizaki, T | 1 |
| Yoshikawa, T | 2 |
| Arisawa, T | 2 |
| Shibata, T | 1 |
| Kamiya, Y | 1 |
| Nagasaka, M | 1 |
| Nakamura, M | 2 |
| Fujita, H | 1 |
| Hasegawa, S | 1 |
| Harata, M | 1 |
| Mizuno, T | 1 |
| Tahara, T | 1 |
| Ohta, Y | 1 |
| Nakano, H | 1 |
| Okazaki, M | 1 |
| Shimizu, I | 1 |
| Ishikawa, M | 1 |
| Yamamoto, H | 1 |
| Shiraishi, T | 1 |
| Horie, T | 1 |
| Iuchi, A | 1 |
| Ito, S | 2 |
| Cho, SH | 1 |
| Han, JY | 1 |
| Kim, JK | 1 |
| Han, SW | 1 |
| Choi, KY | 1 |
| Chung, IS | 1 |
| Ishikawa, T | 1 |
| Kokura, S | 1 |
| Takimoto, T | 1 |
| Ido, K | 1 |
| Taniguchi, Y | 1 |
| Satoh, K | 1 |
| Saifuku, K | 1 |
| Kihira, K | 1 |
| Yoshida, Y | 1 |
| Kimura, K | 1 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Humphries, TJ | 3 |
| Bassion, S | 1 |
| Dekkers, CP | 1 |
| Beker, JA | 2 |
| Thjodleifsson, B | 2 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Dojyo, M | 1 |
| Yamazaki, Y | 1 |
| Miyaji, H | 1 |
| Ito, Y | 1 |
| Suto, H | 1 |
| Kuriyama, M | 1 |
| Kato, T | 1 |
| Kohli, Y | 1 |
| Dekkers, C | 1 |
| Bjaaland, T | 1 |
| Finnegan, V | 1 |
| Williams, MP | 1 |
| Blanshard, C | 1 |
| Millson, C | 1 |
| Sercombe, J | 1 |
| Pounder, RE | 1 |
| Johnson, D | 1 |
| Perdomo, C | 2 |
| Barth, J | 2 |
| Jokubaitis, L | 1 |
| Lanza, F | 1 |
| Bardhan, KD | 1 |
| Niecestro, R | 1 |
| Bardou, M | 1 |
| Hokari, K | 1 |
| Sugiyama, T | 1 |
| Saito, M | 1 |
| Miyagishima, T | 1 |
| Kudo, M | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Komatsu, Y | 1 |
| Mizushima, T | 1 |
| Kagaya, H | 1 |
| Hige, S | 1 |
| Takeda, H | 1 |
| Asaka, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Wong, WM | 1 |
| Yee, YK | 1 |
| Hung, WK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Fung, FM | 1 |
| Tong, TS | 1 |
| Lai, KC | 1 |
| Hu, WH | 1 |
| Yuen, MF | 1 |
| Hui, CK | 1 |
| Lam, SK | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Suzuki, M | 1 |
| Suzuki, H | 1 |
| Kitahora, T | 1 |
| Miyazawa, M | 1 |
| Nagahashi, S | 1 |
| Suzuki, K | 1 |
| Ishii, H | 1 |
| Louis, E | 1 |
| Suzuki, T | 1 |
| Tsukamoto, Y | 2 |
| Goto, H | 2 |
| Hase, S | 1 |
| Asai, J | 1 |
| Sugiyama, S | 1 |
| Kuroiwa, M | 1 |
| Ohara, A | 1 |
| Hoshino, H | 1 |
| Nakazawa, S | 1 |
| Ozawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer.[NCT02638584] | Phase 4 | 176 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori[NCT01922765] | Phase 4 | 540 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for rabeprazole and Gastric Ulcer
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Controlled Clinical Trials as Topic; Duoden | 2000 |
Efficacy of rabeprazole once daily for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
25 trials available for rabeprazole and Gastric Ulcer
| Article | Year |
|---|---|
Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Endoscopic Mucosal Resection; Fema | 2019 |
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duodenal Ulcer; Female; Fibrinolytic Agents; | 2014 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2015 |
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; | 2016 |
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; | 2016 |
[Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2008 |
Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon H | 2010 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Disease Progression; Drug | 2011 |
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti | 2012 |
Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Double-Blind Method; Female; Gastroscopy; Humans; Mal | 2013 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
[Prospective comparative study on protective effect of the proton pump inhibitor and the prostaglandin analog on H. pylori-negative gastric mucosa of healthy subjects against low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aspirin; Benzimidazoles; Enzyme I | 2004 |
[The effect of rabeprazole on gastric pH in patients with gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2004 |
A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Be | 2005 |
Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Duodenal Ulcer; Endoscop | 2007 |
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2008 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 1998 |
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2000 |
A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studie | 2000 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
26 other studies available for rabeprazole and Gastric Ulcer
| Article | Year |
|---|---|
A Retrospective Trial Exploring Erzhu Yiren Decoction in Gastric Ulcer with Spleen Deficiency and Dampness-Heat.
Topics: Capsules; Dinoprostone; Epidermal Growth Factor; Hot Temperature; Humans; Rabeprazole; Retrospective | 2022 |
Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Drug Substitution; Endoscopic Mucosal R | 2018 |
PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin - authors' reply.
Topics: Anti-Ulcer Agents; Aspirin; Duodenal Ulcer; Female; Fibrinolytic Agents; Humans; Male; Rabeprazole; | 2014 |
PPI vs. teprenone in preventing recurrence of ulcers during low-dose aspirin.
Topics: Anti-Ulcer Agents; Aspirin; Duodenal Ulcer; Female; Fibrinolytic Agents; Humans; Male; Rabeprazole; | 2014 |
Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Gastroesophageal Reflux; Humans; Proton | 2008 |
[The first results of the program Effective Eradication in Novosibirsk].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cities; Helicobacter Infections; Helicob | 2008 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
[Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; A | 2009 |
Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclo | 2009 |
Prospective single-arm trial of two-week rabeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Carcinom | 2012 |
[Case report: patient with central nervous system side effects due to lafutidine].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Anti-Ulcer Agents; Central Nervous System Disea | 2012 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cy | 2013 |
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Ad | 2002 |
[Pariet in eradication therapy plans].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 2002 |
A new furoxan NO-donor rabeprazole derivative and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Drug Design; He | 2003 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2004 |
Effects of antisecretory agents on angiogenesis during healing of gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Base Sequence; Benzimidazoles; Biopsy, Needle; Case- | 2005 |
Effects of sucralfate, cimetidine and rabeprazole on mucosal hydroxyproline content in healing of ethanol-hcl-induced gastric lesions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cimetidine; Ethanol; Gastric Mu | 2006 |
Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; 6-Ketoprostaglandin F1 alpha; Adult; Aged; Cyclooxygenase 2 | 2007 |
[Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1998 |
Bile reflux due to disturbed gastric movement is a cause of spontaneous gastric ulcer in W/Wv mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Anti-Ulcer Agents; Benzimida | 1999 |
Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2000 |
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; E | 2002 |
Effects of histamine H2-receptor antagonists and a proton pump inhibitor on the mucosal hydroxyproline content of ethanol-HCl-induced gastric lesions in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benz | 1992 |
Effects of two benzimidazoles as proton pump inhibitors on water immersion stress-induced gastric ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastric | 1991 |